PBYI News and Press, Puma Biotechnology Inc From 10/23/19

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Wednesday, November 6, 2019 following release of its third quarter 2019 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1...

Less than two years ago, Seattle Genetics (NASDAQ: SGEN) received a great deal of criticism for acquiring Cascadian Therapeutics to get its hands on an early clinical-stage cancer drug called tucatinib. Since then, the stock has climbed about 91% thanks to some impressive results from the ex...

Biotech stocks have been underperforming, but the drops in  Puma Biotechnology (NASDAQ: PBYI) , Clovis Oncology (NASDAQ: CLVS) , and Regenxbio (NASDAQ: RGNX) have been downright jaw-dropping. Post-approval sales have been slow to materialize for Puma Biotech and Clovis Oncology, re...

On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...

Cancer drug sales are on track to post an impressive compound annual growth rate of 11.4% over the next five years, according to a report by EvaluatePharma. This double-digit growth rate is particularly noteworthy because cancer drug sales already dwarf all other pharma market segments by a wide...

Gainers:  Asure Software (NASDAQ: ASUR ) +22% . SunLink Health Systems (NYSEMKT: SSY ) +10% . AgeX Therapeutics (NYSEMKT: AGE ) +9% . NIO (NYSE: NIO ) +9% . ATIF Holdings (NASDAQ: ATIF ) +8% . Frontier Communications Corporation (NASDAQ: FTR ) +8% . Nordic American Tankers Limit...

Puma Biotechnology (NASDAQ: PBYI ) discloses that Chief Commercial Officer Steven Lo will resign effective Friday, October 18, to accept the CEO job at another biotech. More news on: Puma Biotechnology, Inc., Healthcare stocks news, Stocks on the move, Read more ...

QIAGEN (NYSE: QGEN )  -18%  on reporting preliminary Q3 results. More news on: QIAGEN N.V., Ocugen, Inc., Ambarella, Inc., Stocks on the move, Read more ...

ChromaDex (NASDAQ: CDXC ) initiated with Outperform rating and $8 (119% upside) price target at Sturdivant. More news on: ChromaDex Corporation, Satsuma Pharmaceuticals, Inc., SpringWorks Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Puma Biotechnology (NASDAQ: PBYI )  surges 13%  in after-hours trading after the U.S. Food and Drug Administration approves a labeling supplement for Nerlynx (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer. More news on: Puma Biotechno...